ReCode Therapeutics
Hu Meng began their career in 2016 as a Research Associate at the University of Pennsylvania. Hu then moved into a Postdoc role at the same institution. In 2022, Hu Meng joined ReCode Therapeutics as a Scientist II.
Hu Meng obtained a Bachelor of Science (B.Sc.) in Chemistry from Peking University in 2009, followed by a Doctor of Philosophy (Ph.D.) in Physical Chemistry from the same university in 2015.
This person is not in the org chart
ReCode Therapeutics
1 followers
ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases.